Protein Summary
Component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.
- ENST00000252674
- ENSP00000252674
- ENSG00000130382
- ENL
- LTG19
- YEATS1
- ENL
- LTG19
- YEATS1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
drug perturbation | 0.87 | ||
ligand (protein) perturbation | 0.83 | ||
transcription factor binding site profile | 0.82 | ||
disease perturbation | 0.74 | ||
tissue sample | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 383.3 (req: < 5)
Gene RIFs: 21 (req: <= 3)
Antibodies: 130 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 383.3 (req: >= 5)
Gene RIFs: 21 (req: > 3)
Antibodies: 130 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 30
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0